Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | FRK | P42685 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18383407 | 0.89 | SCN4A (0.50) | NPC1RAB9AKDM4EALDH1A1GAA | |
| SCHEMBL2028396 | 0.89 | ADH5 (0.32) | — | |
| SCHEMBL13411813 | 0.86 | ADH5 (0.36) | — | |
| SCHEMBL17251287 | 0.85 | MEN1 (0.38) | NPC1RAB9AMAPK13MAPK12MAPK11 | |
| SCHEMBL17254440 | 0.80 | ESR1 (0.33) | — | |
| SCHEMBL24573393 | 0.80 | HSD17B1 (0.42) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL12076659 | 0.79 | MAPK14 (0.44) | KDM4EMAPK14 | |
| SCHEMBL264036 | 0.78 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL595550 | 0.78 | IDO1 (0.35) | — | |
| SCHEMBL595369 | 0.78 | PKM (0.44) | NPC1RAB9ASMN1; SMN2ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932595-B2 | VDR-silent vitamin D derivative as inhibitors of SREBP and pharmaceutical use thereof | KYOTO UNIVERSITY, NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY, TEIKYO UNIVERSITY and THE UNIVERSITY OF TOKYO (JP) | 2024-03-19 | — | — | US | disclosed |
| WO-2024029583-A1 | NOVEL PYRAZOLE DERIVATIVE AND USE OF SAME | 国立研究開発法人理化学研究所 | 2024-02-08 | — | — | WO | disclosed |
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-05-16 | — | — | US | disclosed |
| EP-3976577-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | University of Tennessee Research Foundation (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2022061193-A1 | VDR-SILENT VITAMIN D DERIVATIVE AS INHIBITORS OF SREBP AND PHARMACEUTICAL USE THEREOF | KYOTO UNIVERSITY (JP) | 2022-03-24 | — | — | WO | disclosed |
| US-20220081401-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2022-03-17 | — | — | US | disclosed |
| US-20220081381-A1 | VDR-SILENT VITAMIN D DERIVATIVE AS INHIBITORS OF SREBP AND PHARMACEUTICAL USE THEREOF | KYOTO UNIVERSITY (JP) | 2022-03-17 | — | — | US | disclosed |
| US-11230523-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-01-25 | — | — | US | disclosed |
| CN-113164435-A | Selective Androgen Receptor Degrader (SARD) ligands and methods of use thereof | 田纳西大学研究基金会 | 2021-07-23 | — | — | CN | disclosed |
| US-20210196678-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-07-01 | — | — | US | disclosed |
| US-6277998-B1 | REACTING 2-CYANO-4-OXO-4H-BENZOPYRAN COMPOUND WITH HYDROGEN SULFIDE AND THEN REACTING PROUDCT WITH ALKYL HALIDE; REACTING THE PRODUCT WITH HYDRAZINE OR ITS SALT AND THEN WITH NITROUS ACID COMPOUND TO OBTAIN TETRAZOLE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-08-21 | — | — | US | disclosed |
| US-6191289-B1 | REACTING A 4-OXO-4H-BENZOPYRAN GROUP SUBSTITUTED WITH AMIDE OR A PHENYL GROUP IN ITS 2 POSITION IS REACTED WITH ANHYDROUS HYDRAZINE OR SALT IN PRESENCE OF CATALYST FOLLOWED BY REACTING WITH NITROUS ACID OR SALT TO FORM TETRAZOLE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-02-20 | — | — | US | disclosed |
| US-5874593-A | SULFUR CONTAINING AMIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-02-23 | — | — | US | disclosed |
| US-RE35281-E | ANTIDIABETIC AGENTS | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1996-06-18 | — | — | US | disclosed |
| EP-0711762-A1 | PROCESS FOR PRODUCING TETRAZOLE COMPOUND AND INTERMEDIATE THEREFOR | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-05-15 | — | — | EP | disclosed |
| EP-0388967-B1 | Aldose reductase inhibitor | WAKAMOTO PHARMA CO LTD (JP) | 1995-06-28 | — | — | EP | disclosed |
| US-5055481-A | Alleviate diabetic complications | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1991-10-08 | — | — | US | disclosed |
| EP-0388967-A1 | Aldose reductase inhibitor | Wakamoto Pharmaceutical Co., Ltd. (JP) | 1990-09-26 | — | — | EP | disclosed |
| US-4647572-A | Iodoallyl and iodopropargyl substituted tetrazoles and anti-microbial compositions thereof | MEIJI SEIKA KAISHA, LTD. (JP) | 1987-03-03 | — | — | US | disclosed |
| EP-0107859-A1 | Tetrazole compounds, process for preparing the same and antibacterial and antifungal compositions containing the same as active ingredient | MEIJI SEIKA KAISHA LTD. (JP) | 1984-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230523-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, AHR | NPC1 4393/4885RAB9A 4203/4885SMN1; SMN2 464/4885 |
| US-20220081401-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, AHR | NPC1 4393/4885RAB9A 4203/4885SMN1; SMN2 464/4885 |
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | AR, BRCA1, FSHR | NPC1 4183/4885RAB9A 4305/4885SMN1; SMN2 186/4885 |
| US-11932595-B2 | VDR-silent vitamin D derivative as inhibitors of SREBP and pharmaceutical use thereof | VDR, CYP24A1, CYP2R1 | NPC1 206/4885RAB9A 3090/4885SMN1; SMN2 4749/4885 |
| US-20220081381-A1 | VDR-SILENT VITAMIN D DERIVATIVE AS INHIBITORS OF SREBP AND PHARMACEUTICAL USE THEREOF | VDR, CYP24A1, CYP2R1 | NPC1 206/4885RAB9A 3090/4885SMN1; SMN2 4749/4885 |
| US-20210196678-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, FSHR | NPC1 4456/4885RAB9A 4448/4885SMN1; SMN2 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.